Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.

Li, Zhaoyang; McCoy, Barbara; Engl, Werner; Yel, Leman

Li, Zhaoyang; McCoy, Barbara; Engl, Werner; Yel, Leman.

Affiliation

Li Z; Shire Human Genetic Therapies, Inc., a Takeda company, 650 East Kendall Street, Cambridge, MA, 02142, USA. zhaoyang.li@takeda.com.
McCoy B; Baxalta Innovations GmbH, a Takeda company, Vienna, Austria.
Engl W; Baxalta Innovations GmbH, a Takeda company, Vienna, Austria.
Yel L; Baxalta US Inc., a Takeda company, Cambridge, MA, USA.

J Clin Immunol ; 41(6): 1331-1338, 2021 08.

Article in En | MEDLINE | ID: mdl-34036490

Subject(s)
Key words

Cuvitru; Pharmacokinetics; intravenous immunoglobulin; primary immunodeficiency diseases; subcutaneous immunoglobulin

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulins, Intravenous / Immunologic Deficiency Syndromes Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Clin Immunol Year: 2021 Document type: Article Affiliation country: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google